| Literature DB >> 23991086 |
Francisco Peñagaricano1, Alex H Souza, Paulo D Carvalho, Ashley M Driver, Rocio Gambra, Jenna Kropp, Katherine S Hackbart, Daniel Luchini, Randy D Shaver, Milo C Wiltbank, Hasan Khatib.
Abstract
Maternal nutrition exclusively during the periconceptional period can induce remarkable effects on both oocyte maturation and early embryo development, which in turn can have lifelong consequences. The objective of this study was to evaluate the effect of maternal methionine supplementation on the transcriptome of bovine preimplantation embryos. Holstein cows were randomly assigned to one of two treatments differing in level of dietary methionine (1.89 Met vs. 2.43 Met % of metabolizable protein) from calving until embryo flushing. High quality preimplantation embryos from individual cows were pooled and then analyzed by RNA sequencing. Remarkably, a subtle difference in methionine supplementation in maternal diet was sufficient to cause significant changes in the transcriptome of the embryos. A total of 276 genes out of 10,662 showed differential expression between treatments (FDR <0.10). Interestingly, several of the most significant genes are related to embryonic development (e.g., VIM, IFI6, BCL2A1, and TBX15) and immune response (e.g., NKG7, TYROBP, SLAMF7, LCP1, and BLA-DQB). Likewise, gene set enrichment analysis revealed that several Gene Ontology terms, InterPro entries, and KEGG pathways were enriched (FDR <0.05) with differentially expressed genes involved in embryo development and immune system. The expression of most genes was decreased by maternal methionine supplementation, consistent with reduced transcription of genes with increased methylation of specific genes by increased methionine. Overall, our findings provide evidence that supplementing methionine to dams prior to conception and during the preimplantation period can modulate gene expression in bovine blastocysts. The ramifications of the observed gene expression changes for subsequent development of the pregnancy and physiology of the offspring warrant further investigation in future studies.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23991086 PMCID: PMC3749122 DOI: 10.1371/journal.pone.0072302
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers used for the validation of gene expression.
| Gene | Primer sequence 5′→3′ | Amplicon size (bp) |
|
| F: | 129 |
| R: | ||
|
| F: | 134 |
| R: | ||
|
| F: | 120 |
| R: | ||
|
| F: | 88 |
| R: | ||
|
| F: | 118 |
| R: |
Summary of sequencing read alignments to the reference genome.
| Sample | TotalReads | Total Mapped Reads | Percent Mapped | Uniquely mapped Reads | Percent uniquely mapped | Reads mapped to annotated exons |
| C1.1 | 18,683,178 | 14,865,139 | 80 | 13,804,648 | 93 | 7,579,921 |
| C1.2 | 24,617,256 | 16,065,170 | 65 | 14,644,960 | 91 | 6,668,507 |
| C2.1 | 16,999,297 | 12,754,794 | 75 | 11,670,891 | 92 | 5,624,126 |
| C2.2 | 19,352,730 | 14,232,476 | 74 | 13,064,631 | 92 | 6,461,949 |
| C3.1 | 18,158,624 | 13,692,675 | 75 | 12,524,307 | 91 | 7,423,716 |
| C3.2 | 20,488,552 | 15,917,040 | 78 | 14,282,447 | 90 | 1,745,048 |
| C4.1 | 17,751,765 | 14,181,546 | 80 | 12,937,347 | 91 | 6,066,196 |
| C4.2 | 19,319,918 | 15,736,767 | 81 | 14,532,068 | 92 | 7,778,414 |
| M5.1 | 21,048,132 | 16,307,207 | 77 | 14,993,073 | 92 | 7,257,007 |
| M5.2 | 18,785,042 | 14,273,157 | 76 | 13,063,772 | 92 | 7,578,668 |
| M6.1 | 21,231,578 | 16,546,777 | 78 | 15,056,124 | 91 | 7,339,356 |
| M6.2 | 15,886,593 | 12,745,983 | 80 | 11,738,823 | 92 | 5,941,973 |
| M7.1 | 19,294,383 | 14,642,903 | 76 | 13,280,140 | 91 | 7,826,542 |
| M7.2 | 15,078,732 | 11,628,448 | 77 | 10,663,643 | 92 | 6,582,004 |
| M8.1 | 18,057,137 | 14,080,144 | 78 | 12,768,027 | 91 | 7,184,256 |
| M8.2 | 19,600,350 | 14,327,542 | 73 | 12,981,732 | 91 | 7,405,798 |
Samples belong to control (C) and methionine-rich (M) treatments, respectively. A total of 8 cows, 4 per treatment, were used. Embryos recovered from each cow were pooled in order to generate two replicates per cow assayed.
Figure 1Multidimensional scaling (MDS) plot showing the relative similarities of the samples under study.
Distance between each pair of samples is the square root of the common dispersion based on the top 1,000 genes that best distinguished that pair of samples.
Figure 2Plot of the log2 fold change against average log2 expression.
Gene expression was expressed as counts per million. Horizontal blue lines indicate 2-fold change. Differential expressed genes (FDR <0.10) are highlighted in red.
Top 30 most significant genes that showed differential expression between control and methionine-rich treatment.
| Gene | Name | log2 FC | FDR |
| LAPTM5 | Lysosomal protein transmembrane 5 | −14.9 | 4.7×10−9 |
| NKG7 | Natural killer cell group 7 sequence | −13.6 | 4.4×10−8 |
| VIM | Vimentin | −13.8 | 1.8×10−7 |
| TYROBP | TYRO protein tyrosine kinase binding protein | −13.2 | 3.2×10−6 |
| IFI6 | Interferon, alpha-inducible protein 6 | −12.6 | 1.5×10−5 |
| CUFF.2147.1 |
| −8.2 | 1.5×10−5 |
| LOC505451 | Olfactory receptor, family 1, subfamily J, member 2-like | −13.0 | 1.5×10−5 |
| SLAMF7 | Signaling lymphocyte-activating molecule family 7 family member 7 | −10.4 | 3.5×10−5 |
| LOC788199 | Olfactory receptor 6C74-like | −10.4 | 7.6×10−5 |
| LCP1 | Lymphocyte cytosolic protein 1 (L-plastin) | −9.9 | 1.1×10−4 |
| LOC100849660 |
| 11.9 | 2.2×10−4 |
| BLA-DQB | MHC class II antigen | −11.1 | 2.2×10−4 |
| SHC2 | SHC (Src homology 2 domain containing) transforming protein 2 | −11.5 | 3.4×10−4 |
| NT5C3 | 5′-nucleotidase, cytosolic III | −11.5 | 3.5×10−4 |
| LOC510193 | Apolipoprotein L, 3-like | 7.8 | 4.3×10−4 |
| LOC100848815 | SLA class II histocompatibility antigen, DQ haplotype D alpha chain-like | −11.4 | 4.3×10−4 |
| CUFF.606.1 |
| −5.6 | 4.3×10−4 |
| LOC100850656 |
| −11.2 | 4.8×10−4 |
| SLC11A1 | Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 | −10.7 | 6.9×10−4 |
| LOC100852347 | Beta-defensin 10-like | −11.2 | 7.3×10−4 |
| LOC100297676 | C-type lectin domain family 2 member G-like | −6.8 | 9.2×10−4 |
| BCL2A1 | BCL2-related protein A1 | −7.1 | 1.2×10−3 |
| INSR | Insulin receptor | −5.1 | 1.3×10−3 |
| NOVA1 | Neuro-oncological ventral antigen 1 | −10.6 | 1.5×10−3 |
| TBX15 | T-box 15 | −11.2 | 2.2×10−3 |
| TMEM200C | Transmembrane protein 200C | −6.6 | 2.2×10−3 |
| GPNMB | Glycoprotein (transmembrane) nmb | −7.5 | 2.3×10−3 |
| ARHGAP9 | Rho GTPase activating protein 9 | −5.7 | 2.7×10−3 |
| EIF4E1B | Eukaryotic translation initiation factor 4E family member 1B | −11.3 | 3.1×10−3 |
| LOC100295170 | Protein BEX2-like | −9.3 | 3.5×10−3 |
A negative log2 Fold Change (FC) value means that the gene showed higher expression in control treatment while a positive value means that the gene showed higher expression in methionine-rich treatment.
Figure 3Fold changes of four differentially expressed genes measured by RNA-Seq (blue) versus qRT-PCR (red).
Bars above the X-axis denote genes with higher expression in the methionine-rich treatment while bars below the X-axis denote genes with higher expression in the in control treatment. Importantly, IFI6 was not expressed in methionine-rich pool and hence a fold change was assigned based on the detection threshold of the equipment.
Gene Ontology (GO) biological process terms significantly enriched with differentially expressed genes.
| GO ID | Term | FDR (q-value) |
| 0001763 | Morphogenesis of a branching structure | 0.038 |
| 0006952 | Defense response | 0.004 |
| 0006955 | Immune response | 0.038 |
| 0007166 | Cell surface receptor linked signal transduction | 0.023 |
| 0007186 | G-protein coupled receptor protein signaling pathway | 0.010 |
| 0009611 | Response to wounding | 0.025 |
| 0035295 | Tube development | 0.038 |
| 0048754 | Branching morphogenesis of a tube | 0.037 |